These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Ridker PM Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745 [TBL] [Abstract][Full Text] [Related]
32. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy. Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770 [TBL] [Abstract][Full Text] [Related]
33. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis. Kottoor SJ; Arora RR J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850 [TBL] [Abstract][Full Text] [Related]
34. NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis. Paramel Varghese G; Folkersen L; Strawbridge RJ; Halvorsen B; Yndestad A; Ranheim T; Krohg-Sørensen K; Skjelland M; Espevik T; Aukrust P; Lengquist M; Hedin U; Jansson JH; Fransén K; Hansson GK; Eriksson P; Sirsjö A J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207962 [TBL] [Abstract][Full Text] [Related]
35. Effect of interleukin 1β inhibition in cardiovascular disease. Qamar A; Rader DJ Curr Opin Lipidol; 2012 Dec; 23(6):548-53. PubMed ID: 23069985 [TBL] [Abstract][Full Text] [Related]
36. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Abderrazak A; Couchie D; Mahmood DF; Elhage R; Vindis C; Laffargue M; Matéo V; Büchele B; Ayala MR; El Gaafary M; Syrovets T; Slimane MN; Friguet B; Fulop T; Simmet T; El Hadri K; Rouis M Circulation; 2015 Mar; 131(12):1061-70. PubMed ID: 25613820 [TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Khambhati J; Engels M; Allard-Ratick M; Sandesara PB; Quyyumi AA; Sperling L Atherosclerosis; 2018 Sep; 276():1-9. PubMed ID: 30006321 [TBL] [Abstract][Full Text] [Related]
39. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk. Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836 [TBL] [Abstract][Full Text] [Related]
40. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]